Current Report Filing (8-k)

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

 

Date of Report: March 24, 2017

 

AEOLUS PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware

(State or other jurisdiction of incorporation)

 

0-50481		56-1953785
(Commission File Number)		(IRS Employer Identification No.)

 

26361 Crown Valley Parkway, Suite 150

Mission Viejo, California 92691

(Address of Principal Executive Offices, Including Zip Code)

 

949-481-9825

(Registrant’s Telephone Number, Including Area Code)

__________________

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

 

Item 8.01. Other Events

 

 

Aeolus Pharmaceuticals, Inc. (the “Company”) received notice from the Assistant Secretary for Preparedness and Response (“ASPR”) that the Biomedical Advanced Research and Development Authority (“BARDA”) elected not to exercise additional options under its contract entitled: “Advanced Development of AEOL10150 as a Medical Countermeasure for Pulmonary Injury Associated with ARS and DEARE.” The notification was sent to Aeolus in response to an “In-Process Review” (“IPR”) meeting held with BARDA on February 2, 2017.

 

 

 

 

 

 

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

 

	AEOLUS PHARMACEUTICALS, INC.
Date: March 24, 2017	By:	/s/  David C. Cavalier
		Chairman & Chief Financial Officer